ESMO 2020: Amivantamab with lazertinib in patients with EGFR-mutated non-small cell lung cancer
The CHRYSALIS study (NCT02609776) is evaluating amivantamab, a fully human bispecific antibody that targets epidermal…
Browsing: Amivantamab
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- The OJC Episode 29: Neoadjuvant Therapy in Melanoma with Georgina Long
- AACR 2021: Neoadjuvant nivolumab plus chemotherapy increased pathological complete response rate in CheckMate-816 lung cancer trial
- AACR 2021: Unselected autologous tumour infiltrating lymphocyte therapy shows early promise in patients with metastatic melanoma
- AACR 2021: Novel approach to PRMT5 inhibition that selectively targets the PRMT5/MTA complex in MTAP-deleted cancer models
- AACR 2021: FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers
- AACR2021: Early-onset colorectal cancers – patients of different races
- AACR 2021: Level of chromosomal abnormality in lung cancer may predict immunotherapy response
- AACR 2021: Personalised cancer vaccine given after adjuvant therapy safe, shows early efficacy in multiple tumour types
